APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

AI Pharmaceutical

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global AI Pharmaceutical Market Outlook and Growth Opportunities 2026

Report ID 17406015045 June 2026198 pages

Choose your research edition.

Industry ResearchAI Pharmaceutical Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal AI Pharmaceutical Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal AI Pharmaceutical Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal AI Pharmaceutical Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal AI Pharmaceutical Market Analysis and Forecast 2026-2032186 pages · $4,950 USD

Market perspective

The global AI Pharmaceutical market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for AI Pharmaceutical is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for AI Pharmaceutical is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for AI Pharmaceutical is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the AI Pharmaceutical market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the AI Pharmaceutical market include Noetik, Atomwise, Cradle, Exscientia, Iktos, Insilico Medicine, BenevolentAI, Cyclica and Recursion, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global AI Pharmaceutical market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of AI Pharmaceutical and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents AI Pharmaceutical revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global AI Pharmaceutical market.

AI Pharmaceutical Segment by Company

Noetik

Atomwise

Cradle

Exscientia

Iktos

Insilico Medicine

BenevolentAI

Cyclica

Recursion

Auransa

InveniAI

Pfizer

IBM

AI Pharmaceutical Segment by Type

Artificial intelligence (AI)

Machine Learning (ML)

Others

AI Pharmaceutical Segment by Application

Drug Discovery

Clinical Trials

Others

AI Pharmaceutical Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global AI Pharmaceutical status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the AI Pharmaceutical key companies, revenue, market share, and recent developments.

3. To split the AI Pharmaceutical breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions AI Pharmaceutical market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify AI Pharmaceutical significant trends, drivers, influence factors in global and regions.

6. To analyze AI Pharmaceutical competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AI Pharmaceutical market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of AI Pharmaceutical and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AI Pharmaceutical.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global AI Pharmaceutical industry.

Chapter 3: Detailed analysis of AI Pharmaceutical company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of AI Pharmaceutical in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of AI Pharmaceutical in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. AI Pharmaceutical Industry Trends Table 2. AI Pharmaceutical Industry Drivers Table 3. AI Pharmaceutical Industry Opportunities and Challenges Table 4. AI Pharmaceutical Industry Restraints Table 5. Global AI Pharmaceutical Revenue by Company (US$ Million) & (2021-2026) Table 6. Global AI Pharmaceutical Revenue Share by Company (2021-2026) Table 7. Global AI Pharmaceutical Company Ranking, (2024-2026) & (US$ Million) Table 8. Global AI Pharmaceutical Key Company Manufacturing Base & Headquarters Table 9. Global AI Pharmaceutical Company, Product Type & Application Table 10. Global AI Pharmaceutical Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global AI Pharmaceutical by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Artificial intelligence (AI) Table 15. Significant Companies of Machine Learning (ML) Table 16. Significant Companies of Others Table 17. Global AI Pharmaceutical Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global AI Pharmaceutical Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global AI Pharmaceutical Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global AI Pharmaceutical Sales Value Share by Type (2021-2026) Table 21. Global AI Pharmaceutical Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Drug Discovery Table 23. Significant Companies of Clinical Trials Table 24. Significant Companies of Others Table 25. Global AI Pharmaceutical Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global AI Pharmaceutical Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global AI Pharmaceutical Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global AI Pharmaceutical Sales Value Share by Application (2021-2026) Table 29. Global AI Pharmaceutical Sales Value Share by Application (2027-2032) Table 30. Global AI Pharmaceutical Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global AI Pharmaceutical Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global AI Pharmaceutical Sales Value Share by Region (2021-2026) Table 33. Global AI Pharmaceutical Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global AI Pharmaceutical Sales Value Share by Region (2027-2032) Table 35. Global AI Pharmaceutical Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global AI Pharmaceutical Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global AI Pharmaceutical Sales Value Market Share by Country (2021-2026) Table 38. Global AI Pharmaceutical Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global AI Pharmaceutical Sales Value Market Share by Country (2027-2032) Table 40. Noetik Company Information Table 41. Noetik Business Overview Table 42. Noetik AI Pharmaceutical Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Noetik AI Pharmaceutical Product Portfolio Table 44. Noetik Recent Development Table 45. Atomwise Company Information Table 46. Atomwise Business Overview Table 47. Atomwise AI Pharmaceutical Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Atomwise AI Pharmaceutical Product Portfolio Table 49. Atomwise Recent Development Table 50. Cradle Company Information Table 51. Cradle Business Overview Table 52. Cradle AI Pharmaceutical Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Cradle AI Pharmaceutical Product Portfolio Table 54. Cradle Recent Development Table 55. Exscientia Company Information Table 56. Exscientia Business Overview Table 57. Exscientia AI Pharmaceutical Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Exscientia AI Pharmaceutical Product Portfolio Table 59. Exscientia Recent Development Table 60. Iktos Company Information Table 61. Iktos Business Overview Table 62. Iktos AI Pharmaceutical Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Iktos AI Pharmaceutical Product Portfolio Table 64. Iktos Recent Development Table 65. Insilico Medicine Company Information Table 66. Insilico Medicine Business Overview Table 67. Insilico Medicine AI Pharmaceutical Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Insilico Medicine AI Pharmaceutical Product Portfolio Table 69. Insilico Medicine Recent Development Table 70. BenevolentAI Company Information Table 71. BenevolentAI Business Overview Table 72. BenevolentAI AI Pharmaceutical Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. BenevolentAI AI Pharmaceutical Product Portfolio Table 74. BenevolentAI Recent Development Table 75. Cyclica Company Information Table 76. Cyclica Business Overview Table 77. Cyclica AI Pharmaceutical Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Cyclica AI Pharmaceutical Product Portfolio Table 79. Cyclica Recent Development Table 80. Recursion Company Information Table 81. Recursion Business Overview Table 82. Recursion AI Pharmaceutical Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Recursion AI Pharmaceutical Product Portfolio Table 84. Recursion Recent Development Table 85. Auransa Company Information Table 86. Auransa Business Overview Table 87. Auransa AI Pharmaceutical Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Auransa AI Pharmaceutical Product Portfolio Table 89. Auransa Recent Development Table 90. InveniAI Company Information Table 91. InveniAI Business Overview Table 92. InveniAI AI Pharmaceutical Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. InveniAI AI Pharmaceutical Product Portfolio Table 94. InveniAI Recent Development Table 95. Pfizer Company Information Table 96. Pfizer Business Overview Table 97. Pfizer AI Pharmaceutical Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Pfizer AI Pharmaceutical Product Portfolio Table 99. Pfizer Recent Development Table 100. IBM Company Information Table 101. IBM Business Overview Table 102. IBM AI Pharmaceutical Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. IBM AI Pharmaceutical Product Portfolio Table 104. IBM Recent Development Table 105. Research Programs/Design for This Report Table 106. Authors List of This Report Table 107. Secondary Sources Table 108. Primary Sources List of Figures Figure 1. AI Pharmaceutical Product Image Figure 2. Global AI Pharmaceutical Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global AI Pharmaceutical Market Size (2021-2032) & (US$ Million) Figure 4. Global AI Pharmaceutical Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Artificial intelligence (AI) Image Figure 8. Machine Learning (ML) Image Figure 9. Others Image Figure 10. Global AI Pharmaceutical Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global AI Pharmaceutical Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global AI Pharmaceutical Sales Value Share by Type (2021-2032) Figure 13. Drug Discovery Image Figure 14. Clinical Trials Image Figure 15. Others Image Figure 16. Global AI Pharmaceutical Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global AI Pharmaceutical Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global AI Pharmaceutical Sales Value Share by Application (2021-2032) Figure 19. Global AI Pharmaceutical Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global AI Pharmaceutical Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America AI Pharmaceutical Sales Value (2021-2032) & (US$ Million) Figure 22. North America AI Pharmaceutical Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe AI Pharmaceutical Sales Value (2021-2032) & (US$ Million) Figure 24. Europe AI Pharmaceutical Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific AI Pharmaceutical Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific AI Pharmaceutical Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America AI Pharmaceutical Sales Value (2021-2032) & (US$ Million) Figure 28. South America AI Pharmaceutical Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa AI Pharmaceutical Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa AI Pharmaceutical Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA AI Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada AI Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico AI Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany AI Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France AI Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. AI Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy AI Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain AI Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia AI Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands AI Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries AI Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China AI Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan AI Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea AI Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India AI Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia AI Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia AI Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil AI Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina AI Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile AI Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia AI Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru AI Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia AI Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel AI Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE AI Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey AI Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran AI Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt AI Pharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Artificial intelligence (AI)
  • Machine Learning (ML)
  • Others
Applications
  • Drug Discovery
  • Clinical Trials
  • Others
Companies covered
  • Noetik
  • Atomwise
  • Cradle
  • Exscientia
  • Iktos
  • Insilico Medicine
  • BenevolentAI
  • Cyclica
  • Recursion
  • Auransa
  • InveniAI
  • Pfizer
  • IBM

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global AI Pharmaceutical Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global AI Pharmaceutical Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 AI Pharmaceutical Market Dynamics
  1. 2.1 AI Pharmaceutical Industry Trends
  2. 2.2 AI Pharmaceutical Industry Drivers
  3. 2.3 AI Pharmaceutical Industry Opportunities and Challenges
  4. 2.4 AI Pharmaceutical Industry Restraints
3 AI Pharmaceutical Market by Company
  1. 3.1 Global AI Pharmaceutical Company Revenue Ranking in 2025
  2. 3.2 Global AI Pharmaceutical Revenue by Company (2021-2026)
  3. 3.3 Global AI Pharmaceutical Company Ranking (2024-2026)
  4. 3.4 Global AI Pharmaceutical Company Manufacturing Base and Headquarters
  5. 3.5 Global AI Pharmaceutical Company Product Type and Application
  6. 3.6 Global AI Pharmaceutical Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global AI Pharmaceutical Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 AI Pharmaceutical Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 AI Pharmaceutical Market by Type
  1. 4.1 AI Pharmaceutical Type Introduction
  2. 4.1.1 Artificial intelligence (AI)
  3. 4.1.2 Machine Learning (ML)
  4. 4.1.3 Others
  5. 4.2 Global AI Pharmaceutical Sales Value by Type
  6. 4.2.1 Global AI Pharmaceutical Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global AI Pharmaceutical Sales Value by Type (2021-2032)
  8. 4.2.3 Global AI Pharmaceutical Sales Value Share by Type (2021-2032)
5 AI Pharmaceutical Market by Application
  1. 5.1 AI Pharmaceutical Application Introduction
  2. 5.1.1 Drug Discovery
  3. 5.1.2 Clinical Trials
  4. 5.1.3 Others
  5. 5.2 Global AI Pharmaceutical Sales Value by Application
  6. 5.2.1 Global AI Pharmaceutical Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global AI Pharmaceutical Sales Value by Application (2021-2032)
  8. 5.2.3 Global AI Pharmaceutical Sales Value Share by Application (2021-2032)
6 AI Pharmaceutical Regional Value Analysis
  1. 6.1 Global AI Pharmaceutical Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global AI Pharmaceutical Sales Value by Region (2021-2032)
  3. 6.2.1 Global AI Pharmaceutical Sales Value by Region: 2021-2026
  4. 6.2.2 Global AI Pharmaceutical Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America AI Pharmaceutical Sales Value (2021-2032)
  7. 6.3.2 North America AI Pharmaceutical Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe AI Pharmaceutical Sales Value (2021-2032)
  10. 6.4.2 Europe AI Pharmaceutical Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific AI Pharmaceutical Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific AI Pharmaceutical Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America AI Pharmaceutical Sales Value (2021-2032)
  16. 6.6.2 South America AI Pharmaceutical Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa AI Pharmaceutical Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa AI Pharmaceutical Sales Value Share by Country, 2025 VS 2032
7 AI Pharmaceutical Country-level Value Analysis
  1. 7.1 Global AI Pharmaceutical Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global AI Pharmaceutical Sales Value by Country (2021-2032)
  3. 7.2.1 Global AI Pharmaceutical Sales Value by Country (2021-2026)
  4. 7.2.2 Global AI Pharmaceutical Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA AI Pharmaceutical Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada AI Pharmaceutical Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico AI Pharmaceutical Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany AI Pharmaceutical Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France AI Pharmaceutical Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. AI Pharmaceutical Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy AI Pharmaceutical Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain AI Pharmaceutical Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia AI Pharmaceutical Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands AI Pharmaceutical Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries AI Pharmaceutical Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China AI Pharmaceutical Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan AI Pharmaceutical Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea AI Pharmaceutical Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India AI Pharmaceutical Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia AI Pharmaceutical Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia AI Pharmaceutical Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil AI Pharmaceutical Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina AI Pharmaceutical Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile AI Pharmaceutical Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia AI Pharmaceutical Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru AI Pharmaceutical Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia AI Pharmaceutical Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel AI Pharmaceutical Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE AI Pharmaceutical Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey AI Pharmaceutical Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran AI Pharmaceutical Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt AI Pharmaceutical Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt AI Pharmaceutical Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt AI Pharmaceutical Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Noetik
  2. 8.1.1 Noetik Company Information
  3. 8.1.2 Noetik Business Overview
  4. 8.1.3 Noetik AI Pharmaceutical Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Noetik AI Pharmaceutical Product Portfolio
  6. 8.1.5 Noetik Recent Developments
  7. 8.2 Atomwise
  8. 8.2.1 Atomwise Company Information
  9. 8.2.2 Atomwise Business Overview
  10. 8.2.3 Atomwise AI Pharmaceutical Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Atomwise AI Pharmaceutical Product Portfolio
  12. 8.2.5 Atomwise Recent Developments
  13. 8.3 Cradle
  14. 8.3.1 Cradle Company Information
  15. 8.3.2 Cradle Business Overview
  16. 8.3.3 Cradle AI Pharmaceutical Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Cradle AI Pharmaceutical Product Portfolio
  18. 8.3.5 Cradle Recent Developments
  19. 8.4 Exscientia
  20. 8.4.1 Exscientia Company Information
  21. 8.4.2 Exscientia Business Overview
  22. 8.4.3 Exscientia AI Pharmaceutical Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Exscientia AI Pharmaceutical Product Portfolio
  24. 8.4.5 Exscientia Recent Developments
  25. 8.5 Iktos
  26. 8.5.1 Iktos Company Information
  27. 8.5.2 Iktos Business Overview
  28. 8.5.3 Iktos AI Pharmaceutical Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Iktos AI Pharmaceutical Product Portfolio
  30. 8.5.5 Iktos Recent Developments
  31. 8.6 Insilico Medicine
  32. 8.6.1 Insilico Medicine Company Information
  33. 8.6.2 Insilico Medicine Business Overview
  34. 8.6.3 Insilico Medicine AI Pharmaceutical Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Insilico Medicine AI Pharmaceutical Product Portfolio
  36. 8.6.5 Insilico Medicine Recent Developments
  37. 8.7 BenevolentAI
  38. 8.7.1 BenevolentAI Company Information
  39. 8.7.2 BenevolentAI Business Overview
  40. 8.7.3 BenevolentAI AI Pharmaceutical Revenue and Gross Margin (2021-2026)
  41. 8.7.4 BenevolentAI AI Pharmaceutical Product Portfolio
  42. 8.7.5 BenevolentAI Recent Developments
  43. 8.8 Cyclica
  44. 8.8.1 Cyclica Company Information
  45. 8.8.2 Cyclica Business Overview
  46. 8.8.3 Cyclica AI Pharmaceutical Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Cyclica AI Pharmaceutical Product Portfolio
  48. 8.8.5 Cyclica Recent Developments
  49. 8.9 Recursion
  50. 8.9.1 Recursion Company Information
  51. 8.9.2 Recursion Business Overview
  52. 8.9.3 Recursion AI Pharmaceutical Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Recursion AI Pharmaceutical Product Portfolio
  54. 8.9.5 Recursion Recent Developments
  55. 8.10 Auransa
  56. 8.10.1 Auransa Company Information
  57. 8.10.2 Auransa Business Overview
  58. 8.10.3 Auransa AI Pharmaceutical Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Auransa AI Pharmaceutical Product Portfolio
  60. 8.10.5 Auransa Recent Developments
  61. 8.11 InveniAI
  62. 8.11.1 InveniAI Company Information
  63. 8.11.2 InveniAI Business Overview
  64. 8.11.3 InveniAI AI Pharmaceutical Revenue and Gross Margin (2021-2026)
  65. 8.11.4 InveniAI AI Pharmaceutical Product Portfolio
  66. 8.11.5 InveniAI Recent Developments
  67. 8.12 Pfizer
  68. 8.12.1 Pfizer Company Information
  69. 8.12.2 Pfizer Business Overview
  70. 8.12.3 Pfizer AI Pharmaceutical Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Pfizer AI Pharmaceutical Product Portfolio
  72. 8.12.5 Pfizer Recent Developments
  73. 8.13 IBM
  74. 8.13.1 IBM Company Information
  75. 8.13.2 IBM Business Overview
  76. 8.13.3 IBM AI Pharmaceutical Revenue and Gross Margin (2021-2026)
  77. 8.13.4 IBM AI Pharmaceutical Product Portfolio
  78. 8.13.5 IBM Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst